Cargando…

Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database

BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhaliwal, Amaninder, Dhindsa, Banreet, Ramai, Daryl, Sayles, Harlan, Chandan, Saurabh, Rangray, Rajani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157704/
https://www.ncbi.nlm.nih.gov/pubmed/35721288
http://dx.doi.org/10.4254/wjh.v14.i5.984
_version_ 1784718692999757824
author Dhaliwal, Amaninder
Dhindsa, Banreet
Ramai, Daryl
Sayles, Harlan
Chandan, Saurabh
Rangray, Rajani
author_facet Dhaliwal, Amaninder
Dhindsa, Banreet
Ramai, Daryl
Sayles, Harlan
Chandan, Saurabh
Rangray, Rajani
author_sort Dhaliwal, Amaninder
collection PubMed
description BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS) database to compare the survival rates between the hepatitis C positive donors and negative recipients and hepatitis C negative donors and recipients. METHODS: We analyzed the adult patients in UNOS database who underwent deceased donor liver transplant from January 2014 to December 2017. The primary endpoint was to compare the survival rates among the four groups with different hepatitis C donor and recipient status: (Group 1) Both donor and recipient negative for HCV (Group 2) Negative donor and positive recipient for HCV (Group 3) Positive donor and negative recipient for HCV (Group 4) Both positive donor and recipient for HCV. SAS 9.4 software was used for the data analysis. Kaplan Meier log rank test was used to analyze the estimated survival rates among the four groups. RESULTS: A total of 24512 patients were included: Group 1: 16436, Group 2: 6174, Group 3: 253 and Group 4: 1649. The 1-year (Group 1: 91.8%, Group 2: 92.12%, Group 3: 87%, Group 4: 92.8%), 2-year (Group 1: 88.4%, Group 2: 88.1%, Group 3: 84.3%, Group 4: 87.5%), 3-year (Group 1: 84.9%, Group 2: 84.3%, Group 3: 75.9%, Group 4: 83.2%) survival rates showed no statistical significance among the four groups. Kaplan Meier log rank test did not show any statistical significance difference in the estimated survival rates between Group 3 vs all the other groups. CONCLUSION: The survival rates in hepatitis C positive donors and negative recipients are similar as compared to both hepatitis C negative donors and recipients. This could be due to the use of DAA therapy with cure rates of nearly 100%. This study supports the use of hepatitis C positive organs in the selected group of recipients with and without HCV infection. Further long-term studies are needed to further validate these findings.
format Online
Article
Text
id pubmed-9157704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-91577042022-06-17 Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database Dhaliwal, Amaninder Dhindsa, Banreet Ramai, Daryl Sayles, Harlan Chandan, Saurabh Rangray, Rajani World J Hepatol Retrospective Study BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS) database to compare the survival rates between the hepatitis C positive donors and negative recipients and hepatitis C negative donors and recipients. METHODS: We analyzed the adult patients in UNOS database who underwent deceased donor liver transplant from January 2014 to December 2017. The primary endpoint was to compare the survival rates among the four groups with different hepatitis C donor and recipient status: (Group 1) Both donor and recipient negative for HCV (Group 2) Negative donor and positive recipient for HCV (Group 3) Positive donor and negative recipient for HCV (Group 4) Both positive donor and recipient for HCV. SAS 9.4 software was used for the data analysis. Kaplan Meier log rank test was used to analyze the estimated survival rates among the four groups. RESULTS: A total of 24512 patients were included: Group 1: 16436, Group 2: 6174, Group 3: 253 and Group 4: 1649. The 1-year (Group 1: 91.8%, Group 2: 92.12%, Group 3: 87%, Group 4: 92.8%), 2-year (Group 1: 88.4%, Group 2: 88.1%, Group 3: 84.3%, Group 4: 87.5%), 3-year (Group 1: 84.9%, Group 2: 84.3%, Group 3: 75.9%, Group 4: 83.2%) survival rates showed no statistical significance among the four groups. Kaplan Meier log rank test did not show any statistical significance difference in the estimated survival rates between Group 3 vs all the other groups. CONCLUSION: The survival rates in hepatitis C positive donors and negative recipients are similar as compared to both hepatitis C negative donors and recipients. This could be due to the use of DAA therapy with cure rates of nearly 100%. This study supports the use of hepatitis C positive organs in the selected group of recipients with and without HCV infection. Further long-term studies are needed to further validate these findings. Baishideng Publishing Group Inc 2022-05-27 2022-05-27 /pmc/articles/PMC9157704/ /pubmed/35721288 http://dx.doi.org/10.4254/wjh.v14.i5.984 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Dhaliwal, Amaninder
Dhindsa, Banreet
Ramai, Daryl
Sayles, Harlan
Chandan, Saurabh
Rangray, Rajani
Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title_full Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title_fullStr Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title_full_unstemmed Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title_short Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
title_sort impact of utilization of hepatitis c positive organs in liver transplant: analysis of united network for organ sharing database
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157704/
https://www.ncbi.nlm.nih.gov/pubmed/35721288
http://dx.doi.org/10.4254/wjh.v14.i5.984
work_keys_str_mv AT dhaliwalamaninder impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase
AT dhindsabanreet impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase
AT ramaidaryl impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase
AT saylesharlan impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase
AT chandansaurabh impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase
AT rangrayrajani impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase